Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: pancreatic cancer. Displaying page 16 of 26.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2017-001394-16 Sponsor Protocol Number: GCT1029-01 Start Date*: 2018-03-29
    Sponsor Name:Genmab B.V.
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors
    Medical condition: Malignant solid tumors: Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002094-22 Sponsor Protocol Number: FiHM006 Start Date*: 2019-01-17
    Sponsor Name:Fundación de investigación de HM Hospitales
    Full Title: A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients with Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant NALIRINOX
    Medical condition: Resectable Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000588-53 Sponsor Protocol Number: SNIPER Start Date*: 2023-02-07
    Sponsor Name:RIGENERAND Srl
    Full Title: RR001 in combination with chemotherapy for patients with locally advanced pancreatic adenocarcinoma: open-label, non-randomized dose escalation phase I/IIa study
    Medical condition: Locally advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005790-60 Sponsor Protocol Number: CL-SBP-101-04 Start Date*: 2022-08-05
    Sponsor Name:Panbela Therapeutics, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Temporarily Halted) IT (Prematurely Ended) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002877-30 Sponsor Protocol Number: CSOM230B2212 Start Date*: 2006-12-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning ad...
    Medical condition: duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adenoma, TSH-adenoma,Gonadotroph adenoma, and PRL-adenoma)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035098 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004792-30 Sponsor Protocol Number: HE316 Start Date*: 2018-10-03
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma
    Medical condition: Advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003080-26 Sponsor Protocol Number: CASSANDRA Start Date*: 2020-10-14
    Sponsor Name:FONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE)
    Full Title: A randomized phase II trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC).
    Medical condition: Patients with pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002293-41 Sponsor Protocol Number: AB12005 Start Date*: 2015-07-02
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to g...
    Medical condition: Non resectable locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) DE (Prohibited by CA) SK (Prohibited by CA) GR (Completed) GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2006-005703-34 Sponsor Protocol Number: ageo02 Start Date*: 2007-05-14
    Sponsor Name:Ageo
    Full Title: Essai de phase II : Folfiri.3 (CPT-11/acide folinique/5-FU) / gemzar en traitement sequentiel des cancers du pancréas métastatiques non pré-traités
    Medical condition: The trial will evaluate a sequential chemotherapy in patient suffering from metastatic pancreatic carcinoma which had not been treated in the past.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033610 Pancreatic carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002026-52 Sponsor Protocol Number: ACCORD 24/0610 (PRODIGE 24) Start Date*: 2011-10-11
    Sponsor Name:Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003165-34 Sponsor Protocol Number: IRST100.11 Start Date*: 2013-12-03
    Sponsor Name:IRCCS-IRST of Meldola
    Full Title: Peptide Receptor Radionuclide Therapy (PRRT) with Radiolabelled Somatostatin Analogue 177Lu-DOTATATE in advanced gastro-entero-pancreatic Neuroendocrine Tumors, FDG-PET negative patients: a prospe...
    Medical condition: Advanced gastro-entero-pancreatic Neuroendocrine Tumors, FDG-PET negative patients
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014713 Endocrine neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003172-12 Sponsor Protocol Number: KY1044-CT01 Start Date*: 2019-03-07
    Sponsor Name:Kymab Ltd
    Full Title: A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies
    Medical condition: Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, ga...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077738 Hepatocellular carcinoma metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007416 Carcinoma liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002206-52 Sponsor Protocol Number: CD-ON-MEDI4736-1108 Start Date*: 2012-12-05
    Sponsor Name:MedImmune
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005530-42 Sponsor Protocol Number: imPaCT-PRO-01 Start Date*: 2021-12-07
    Sponsor Name:Institute of Molecular Medicine and Biomedical Research (IMBE)
    Full Title: The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study
    Medical condition: Thromboprophylaxis in patients with advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10043607 Thrombosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068067 Tumour thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004356-30 Sponsor Protocol Number: PCYC-1145-LT Start Date*: 2020-03-11
    Sponsor Name:Pharmacyclics Switzerland GmbH, an AbbVie company
    Full Title: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043515 Throat cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054695 Waldenstrom's macroglobulinemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042080 Stomach cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    20.0 100000004870 10018799 GVHD LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) GR (Completed) CZ (Trial now transitioned) DE (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004363-74 Sponsor Protocol Number: A6181202 Start Date*: 2012-02-02
    Sponsor Name:Pfizer Inc.
    Full Title: A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRE...
    Medical condition: PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) HU (Completed) ES (Completed) BE (Completed) PT (Completed) PL (Completed) SK (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004150-17 Sponsor Protocol Number: 341-15 Start Date*: 2015-12-11
    Sponsor Name:Västra Götalandsregionen
    Full Title: The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
    Medical condition: Weight loss and malnutrition after curative surgery for upper gastrointestinal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005110-34 Sponsor Protocol Number: ICT01-102 Start Date*: 2022-02-08
    Sponsor Name:ImCheck Therapeutics, Inc.
    Full Title: A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advance...
    Medical condition: Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pa...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000850-78 Sponsor Protocol Number: IB2019-01 Start Date*: 2021-01-20
    Sponsor Name:Institut Bergonié
    Full Title: Atezolizumab combined with BDB001 and immunogenic radiotherapy in participants with advanced solid tumors.
    Medical condition: - pancreatic cancer - virus-associated tumors - non-small cell lung cancer - soft-tissue sarcoma - bladder cancer - Triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005012 Bladder cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000338-38 Sponsor Protocol Number: OSAG 101 – PCS-07 Start Date*: 2007-07-06
    Sponsor Name:Oncoscience AG
    Full Title: A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREAMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH...
    Medical condition: Locally advanced or metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 18:05:25 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA